APA (7th ed.) Citation

Wakabayashi, H., Inada, H., Nishioka, Y., Hasegawa, M., Nishioka, K., & Sudo, A. (2017). Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events. Drugs in R&D, 17(1), 233. https://doi.org/10.1007/s40268-016-0162-8

Chicago Style (17th ed.) Citation

Wakabayashi, Hiroki, Hitoshi Inada, Yosuke Nishioka, Masahiro Hasegawa, Kusuki Nishioka, and Akihiro Sudo. "Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events." Drugs in R&D 17, no. 1 (2017): 233. https://doi.org/10.1007/s40268-016-0162-8.

MLA (9th ed.) Citation

Wakabayashi, Hiroki, et al. "Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events." Drugs in R&D, vol. 17, no. 1, 2017, p. 233, https://doi.org/10.1007/s40268-016-0162-8.